New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For ABBV;ABT;ALJ;ALDW;FB;WGP;WES;LRCX;WHF From The Last 14 Days
Check below for free stories on ABBV;ABT;ALJ;ALDW;FB;WGP;WES;LRCX;WHF the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | all recent news | >>
September 21, 2014
16:02 EDTFBFacebook's Oculus gets closer to consumer release of Rift headset, FT says
Subscribe for More Information
September 19, 2014
11:25 EDTABTSenators bring bill requiring companies to settle before inverting
U.S. Senators Sherrod Brown and Dick Durbin announced new legislation requiring corporations to "Pay What You Owe Before You Go" – settling their U.S. tax bill before relocating to a foreign country. "Everyone knows that before you leave a restaurant you have to settle your tab," Brown said. "Corporations shouldn’t get to play by different rules. While it is critical that we reach a long-term solution that reforms our international corporate tax code by implementing a global minimum tax and reducing the statutory tax rate, this bill is an immediate, commonsense measure to ensure businesses settle up before leaving the U.S." Among the deals or possible transactions that involve inversion are Mylan's (MYL) acquisition of Abbott (ABT), Medtronic's (MDT) acquisition of Covidien (COV) and Valeant's (VRX) proposed takeover of Allergan (AGN).
11:24 EDTFBTD Ameritrade:Alibaba premarket orders approaching Facebook levels, Reuters says
Subscribe for More Information
September 18, 2014
13:54 EDTFBAd dollars on Facebook outpacing amount of time people spend on site, WSJ says
Subscribe for More Information
13:27 EDTFBFacebook updates story ranking criteria
Subscribe for More Information
12:07 EDTFBStocks with call strike movement; JCP FB
Subscribe for More Information
11:15 EDTABBVRepros sinks after panel backs tests for testosterone therapies
Subscribe for More Information
07:06 EDTFBFacebook volatility low into Alibaba IPO
Subscribe for More Information
06:10 EDTABBVFDA panel votes 20-1 to study changes to testosterone therapies
Subscribe for More Information
September 17, 2014
10:04 EDTFBDiscover rumored to be eyed as target by Apple, Bank Innovation says
Subscribe for More Information
09:40 EDTFBFacebook polishing micro-sharing app 'Moments', TechCrunch reports
Facebook is polishing a new app codenamed "Moments" for micro-sharing for a select group of friends, reports TechCrunch. According to multiple sources, including who has seen a live internal version of the app, the design features a grid with a few tiles, each representing a set of close family or friends. The goal is to make selective sharing much faster than the main Facebook app. Reference Link
September 16, 2014
11:51 EDTABTOECD looks to close tax loopholes with new proposals
Subscribe for More Information
09:36 EDTFBActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL NFLX TSLA YHOO FB PBR MU AA TWTR WMT
07:19 EDTFBFacebook engagement metrics remain strong, says JPMorgan
Subscribe for More Information
September 15, 2014
16:00 EDTFBOptions Update; September 15, 2014
iPath S&P 500 VIX Short-Term Futures up 73c to 29.34 Option volume leaders: AAPL TSLA NFLX BAC TWTR AMZN BP NFLX YHOO FB VLO according to Track Data.
13:53 EDTFBFacebook breaks uptrend, levels to watch
Subscribe for More Information
10:55 EDTABBVRegulators to determine AbbVie, Shire deal by next month, Reuters says
Subscribe for More Information
09:32 EDTABTAbbott initiates ABSORB IV trial
Abbott announced the start of the ABSORB IV clinical trial, which will test whether its Absorb Bioresorbable Vascular Scaffold is more cost-effective and offers a higher quality of life than a permanent, metallic drug eluting stent. Unlike a metallic stent, Absorb completely dissolves over time after doing its job. ABSORB IV is designed to enroll approximately 3K people with coronary artery disease, mostly in the U.S. The ABSORB IV trial is designed to confirm these novel findings that treatment with the Absorb device can help provide people with heart disease a higher quality of life after a heart stent procedure. The data from the ABSORB IV trial will be combined with the data from the ABSORB III trial to create a population of more than 5K people studied in the U.S. This data set, which is the largest of its kind for bioresorbable heart devices, provides an opportunity to evaluate the performance of Absorb compared to the current standard of a metallic drug eluting stent across a number of measures, including the broader health economic impact of this innovative therapy.
07:45 EDTABTCardiovascular Research Foundation to hold a conference
Transcatheter Cardiovascular Therapeutics: TCT 2014 to be held in Washington, D.C. on September 13-17 with some presentations being webcasted. Webcast Link
07:24 EDTFBTech leaders concede need to address privacy, security concerns, FT says
Prominent start-up investor and Facebook (FB) director Peter Thiel said a "crescendo of concern is building up in Europe" about the U.S. tech industry's record on online privacy and security, which Silicon Valley is underestimating "badly,” though Google (GOOG) chairman Eric Schmidt tech companies "are way sensitive" to the concerns, reported Financial Times. The same report noted that Brad Smith, general counsel of Microsoft (MSFT), said some in the industry have "underestimated the degree to which people care about privacy,” while Salesforce.com (CRM) CEO Marc Benioff said consumer Internet companies have “paid a terrible price” for imposing a U.S.-centric view of their technology. Reference Link
06:18 EDTFBFacebook hires Google satellite exec Michael Tseytlin, WSJ reports
Facebook (FB) has hired Michael Tseytlin, a Google (GOOG) executive working to deliver Internet service via satellite, the Wall Street Journal reports. According to sources, Tseytlin will work on satellite technology for Facebook's Connectivity Lab. Reference Link
06:14 EDTFBFacebook implied volatility of 27 at lower end of index mean range
Subscribe for More Information
September 14, 2014
13:30 EDTABTAbbott announces positive one-year clinical results from ABSORB II
Subscribe for More Information
12:51 EDTLRCXLam Research shares could return 20%, Barron's says
Lam Research could rise to $86.00 in a year, driven by market share, and could return more than 20%, including dividends, Barron's contends in a feature article. Reference Link
September 12, 2014
07:32 EDTABBVBiogen, AbbVie announce ZINBRYTA DECIDE Phase 3 study results
Biogen (BIIB) and AbbVie (ABBV) announced the full results from the Phase 3 DECIDE clinical trial, which show ZINBRYTA, dosed subcutaneously once a month, demonstrated a statistically significant improvement in reducing disease activity in people with relapsing-remitting multiple sclerosis compared to AVONEX. These results are being presented at the Sixth Triennial Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis. Patients on ZINBRYTA demonstrated a statistically significant 45% reduction in annualized relapse rate compared to patients treated with AVONEX. Based on the efficacy and safety data from the ZINBRYTA clinical development program, Biogen Idec and AbbVie plan to file marketing applications for ZINBRYTA with regulatory authorities during 1H15.
06:17 EDTFBFacebook looks to lure YouTube's video content providers, WSJ reports
Subscribe for More Information
September 11, 2014
13:41 EDTABTAbbott announces new $3B share repurchase program
Subscribe for More Information
07:02 EDTFBFacebook Q3 estimates have potential upside, says Citigroup
Subscribe for More Information
06:02 EDTFBFacebook implied volatility of 26 at lower end of index mean range
Subscribe for More Information
05:34 EDTABBVAbbVie reports Humira Phase 3 trial meets primary endpoint
Subscribe for More Information
September 10, 2014
12:04 EDTFBFacebook testing tool that lets users schedule post deletions, The Next Web says
Facebook is testing a tool that will allow users to create self-destructing Facebook posts that disappear after a specified period of time, The Next Web reports. A spokesperson has confirmed, saying "We’re running a small pilot of a feature on Facebook for iOS that lets people schedule deletion of their posts in advance." Reference Link
10:24 EDTABBVEnanta announces AbbVie initiated Phase 2b trial with ABT-493
Enanta (ENTA) announced that AbbVie (ABBV) initiated a phase 2b clinical study with ABT-493, Enanta’s next-generation protease inhibitor. ABT-493 is the second clinical-stage protease inhibitor candidate developed within the Enanta-AbbVie collaboration. The phase 2b study being conducted by AbbVie will evaluate the safety and efficacy of ABT-493 co-administered with ABT-530 in HCV patients. AbbVie has informed Enanta that results from this trial are expected in 2015 and AbbVie plans to start phase 3 development of the combination next year.
08:10 EDTALJAlon USA Energy receives approval for Bakersfield rail and refinery project
Subscribe for More Information
September 9, 2014
14:32 EDTFBApple shows Facebook, Twitter apps on Apple Watch
09:36 EDTFBActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL KNDI NFLX YHOO TWTR TSLA C BAC FB MCD
07:17 EDTFBThe Wireless Association to hold a conference
Subscribe for More Information
06:42 EDTABTLew expects to make decision on combating inversion deals soon, NY Times reports
Subscribe for More Information
September 8, 2014
14:00 EDTFBFacebook averages more than 1B video views per day, introducing video views
Subscribe for More Information
12:40 EDTABBVFTC sues AbbVie over blocking of AndroGel generics
The Federal Trade Commission has filed a complaint in federal district court charging several pharmaceutical companies with "illegally blocking American consumers’ access to lower-cost versions of the blockbuster drug AndroGel." The FTC's complaint alleges that AbbVie (ABBV) and its partner Besins Healthcare filed baseless patent infringement lawsuits against potential generic competitors to delay the introduction of lower-priced versions of the testosterone replacement drug AndroGel. While the lawsuits were pending, AbbVie then entered into an anticompetitive pay-for-delay settlement agreement with Teva Pharmaceuticals (TEVA) to further delay generic drug competition, the FTC claims. Reference Link
10:00 EDTFBFacebook may soon enter China, DoNews reports
Subscribe for More Information
09:40 EDTFBActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL TWTR TSLA YHOO BAC FB MSFT NFLX GILD MCD
08:39 EDTALJRail decision on Tuesday could add $7 to Alon USA Energy, says Credit Suisse
Credit Suisse said the Kern County Board will announce its decision on Alon USA Energy's Bakersfield project on Tuesday. The analyst believes this may add $7 per share when constructed, and could allow Alon USA Energy to launch its own MLP. Shares are Outperform rated with a $21 price target.
07:15 EDTABBVIBC Life Sciences to hold a conference
10th Annual Cell Line Development & Engineering Conference to be held in Berkeley, California on September 8-10.
06:34 EDTFBFacebook's Zuckerberg sees WhatsApp reaching up to 3B users, WSJ reports
Speaking at an event in Mexico City, Facebook CEO Mark Zuckerberg says messaging service WhatsApp could reach two to three billion users through a tie-up with Facebook, though WhatsApp will stay an independent service, the Wall Street Journal reports. Facebook agreed to pay $19B for WhatsApp earlier this year. Reference Link
September 7, 2014
14:24 EDTFBFacebook CEO ready to spend billions to spread internet access, Bloomberg says
Subscribe for More Information
<< 1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use